Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

PURPOSE: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who had experienced p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Ferris, Robert L., Licitra, Lisa, Fayette, Jerome, Even, Caroline, Blumenschein, George, Harrington, Kevin J., Guigay, Joel, Vokes, Everett E., Saba, Nabil F., Haddad, Robert, Ramkumar, Shanmugasundaram, Russell, Jeffery, Brossart, Peter, Tahara, Makoto, Colevas, A. Dimitrios, Concha-Benavente, Fernando, Lynch, Mark, Li, Li, Gillison, Maura L.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7721346/
https://ncbi.nlm.nih.gov/pubmed/31239321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3944
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky